References
- Dennerstein L, Smith AMA, Morse C, et al. Menopausal symptoms in Australian women. Med J Aust 1993;159:232–6
- McKinlay SM, Brambilla DJ, Posner JG. The normal menopause transition. Maturitas 1992; 14:103–15
- Oldenhave A, Jaszmann LJB, Haspels AA, Everaerd WTAM. Impact of climacteric on well-being. Am J Obstet Gynecol 1993;168:772–80
- Feldman BM, Voda A, Gronseth E. The preva-lence of hot flash and associated variables among perimenopausal women. Res Nurse Health 1985;8:261–8
- Guthrie JR, Dennerstein L, Hopper JL, Burger HG. Hot flushes, menstrual status, and hormone levels in a population-based sample of midlife women. Obstet Gynecol 1996;88:437–42
- Oldenhave A, Jaszmann u, Everaerd WT, Haspels AA. Hysterectomized women with ovarian conservation report more severe climac-teric complaints than do normal climacteric women of similar age. Am J Obstet Gynecol 1993;168:765–71
- Berg G, Gottwall T, Hammar M, et al. Climac-teric symptoms among women aged 60-62 in Linkoping, Sweden, in 1986. Maturitas 1988; 10:193–9
- Cardozo L, Bachmann G, McClish D, Fonda D, Birgerson L. Meta-analysis of estrogen therapy in the management of urogenital atrophy in post-menopausal women: second report of the Hormones and Urogenital Therapy Committee. Obstet Gynecol 1998;92:722–7
- Bachmann GA, Nevadunsky NS. Diagnosis and treatment of atrophic vaginitis. Am Fam Physician 2000;61:3090–6
- Kaufman JM. Pharmacokinetics of oestrogens and hormone replacement therapy. Eur Meno-pause J 1997;4:14–22
- Ettinger B, Pressman A. Continuation of post-menopausal hormone replacement therapy in a large health maintenance organization: trans-dermal matrix patch versus oral estrogen therapy. Am J Managed Care 1999;5:779–85
- Notelovitz M. Urogenital atrophy and low-dose vaginal estrogen therapy [Editorial]. Menopause 2000;7:140–2
- Woolfson AD, Elliott GRE, Gilligan CA, Passmore CM. Design of an intravaginal ring for the controlled delivery of 170-estradiol as its 3-acetate ester. J Control Release 1999;61: 319–28
- Passmore C, McNamee B, de Vries T. Serum estradiol concentrations following single-dose administration of a novel estradiol acetate intravaginal ring (IVR) delivering 50, 75, and 100 jig/day estradiol in healthy postmenopausal women. Presented at the British Menopause Society Meeting, Birmingham, England, June 2001
- Manson JE, Martin KA. Postmenopausal hormone-replacement therapy. N Engl J Med 2001;345:34–40
- McNagny SE. Prescribing hormone replacement therapy for menopausal symptoms. Ann Intern Med 1999;131:605–16
- Henriksson L, Stjernquist M, Boquist L, Cedergren I, Selinus I. A one-year multicenter study of efficacy and safety of a continuous, low-dose, estradiol-releasing vaginal ring (Estring) in postmenopausal women with symp-toms and signs of urogenital aging. Am J Obstet Gynecol 1996;174:85–92
- Barentsen R, van de Weijer PH, Schram JH. Continuous low dose estradiol released from a vaginal ring versus estriol vaginal cream for urogenital atrophy. Eur J Obstet Gynecol Reprod Biol 1997;71:73–80
- Ayton RA, Darling GM, Murkies AL, et al. A comparative study of safety and efficacy of continuous low dose oestradiol released from a vaginal ring compared with conjugated equine oestrogen vaginal cream in the treatment of urogenital atrophy. Br J Obstet Gynaecol 1996; 103:351–8
- Casper F, Petri E. Local treatment of urogenital atrophy with an estradiol-releasing vaginal ring: a comparative and a placebo-controlled multi-center study. Int Urogynecol J Pelvic Floor Dysfunct 1999;10:171–6
- Buckler HM. Acceptability of use of an estradiol acetate vaginal ring by a community-based population of postmenopausal women. Menopause 2002;9:495–6